BioWorld

Nov. 23, 2009

View Archived Issues

BioCryst $49M Public Offering Cashes in on Stock Momentum

BioCryst Pharmaceuticals Inc. priced a $49 million public offering, cashing in on the 593 percent gain its shares have posted so far this year thanks to progress with flu drug peramivir. (BioWorld Today) Read More

Lawmakers Suspect 'Back-door' Move to Recoup Drug Price Cuts

Read More

Novavax $21M Stock Sale Would Fund U.S. Filing for VLP Vaccine

Read More

In Today's 'Bench Press': Tech Transfer Impact

Read More

Corrections & Clarifications

Read More

Other News To Note

Read More

Clinic Roundup

Read More

Appointments And Advancements

Read More

Bench Press

Read More